Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1346-1347 (10 June), doi:10.1136/bmj.332.7554.1346
No
| The first 150 words of the full text of this article appear below. |
Antipsychotic drugs have been essential in treating schizophrenia since chlorpromazine was introduced in the mid 1950s. By 1980 over 20 other antipsychotic medications were available, and all of them are now sold as generics. Ever since clozapine was shown in the late 1980s to be more effective for treatment resistant patients with schizophrenia than the older antipsychotic agents,1 numerous new antipsychotic drugs have been synthesised and released, with claims of greater efficacy and better tolerability than the older generic agents. Are these claims true, and how should clinicians go about choosing the appropriate drug for their patients with schizophrenia?
Several authoritative and widely adopted treatment guidelines for the use of antipsychotics, such as the TIMA algorithm (Texas Implementation of Medication Algorithms), recommend only the newer antipsychotic drugs as first and second line treatments, reinforcing the perception that the older drugs are therapeutically inferior. These new antipsychotics are often referred
Rohan Ganguli, professor of psychiatry, pathology, and health and community systems
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
(gangulir@upmc.edu)
Martin Strassnig, resident in psychiatry
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Read all Rapid Responses